{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:13:05Z","timestamp":1788988385576,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108003"],"award-info":[{"award-number":["82020108003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330008"],"award-info":[{"award-number":["82330008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200133"],"award-info":[{"award-number":["82200133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500285"],"award-info":[{"award-number":["82500285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016334","name":"Jiangsu Provincial Medical Center","doi-asserted-by":"publisher","award":["CXZX202201"],"award-info":[{"award-number":["CXZX202201"]}],"id":[{"id":"10.13039\/501100016334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","award":["BXLC2024010"],"award-info":[{"award-number":["BXLC2024010"]}],"id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20240354"],"award-info":[{"award-number":["BK20240354"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.04.052","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:08:56Z","timestamp":1778285336000},"page":"1119.e1-1119.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Low-Dose Rituximab as Preemptive Treatment of EBV DNA-emia After Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5539-0849","authenticated-orcid":false,"given":"Yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aining","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtct.2026.04.052_bib0001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOH.0000000000000083","article-title":"Epstein\u2013barr virus lymphoproliferative disease after hematopoietic stem cell transplant:","volume":"21","author":"Rouce","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.052_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2108","article-title":"Epstein-barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation","volume":"30","author":"Lindsay","year":"2020","journal-title":"Rev Med Virol"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.052_bib0003","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1399-3062.2009.00410.x","article-title":"Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative epstein-barr virus polymerase chain reaction","volume":"11","author":"Omar","year":"2009","journal-title":"Transpl Infect Dis: Off J Transplant Soc"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.052_bib0004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of epstein-barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth european conference on infections in leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.052_bib0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second european conference on infections in leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.052_bib0006","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10428194.2018.1459603","article-title":"Single dose versus multiple doses of rituximab for preemptive therapy of epstein\u2013barr virus reactivation after hematopoietic cell transplantation","volume":"60","author":"Jain","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.052_bib0007","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.052_bib0008","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.052_bib0009","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.052_bib0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ejh.13708","article-title":"A low-dose rituximab regimen for first-line treatment of acquired haemophilia a","volume":"108","author":"Hunt","year":"2022","journal-title":"Eur J Haematol"},{"issue":"13","key":"10.1016\/j.jtct.2026.04.052_bib0011","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.2019000795","article-title":"Adjuvant low-dose rituximab and plasma exchange for acquired TTP","volume":"134","author":"Zwicker","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.052_bib0012","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.retram.2019.03.001","article-title":"Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation","volume":"67","author":"Delapierre","year":"2019","journal-title":"Current Research in Translational Medicine"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.052_bib0013","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jcyt.2018.02.367","article-title":"Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder","volume":"20","author":"Kalra","year":"2018","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.052_bib0014","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3390\/curroncol31050211","article-title":"Epstein\u2013barr virus monitoring after an allogeneic hematopoietic stem cell transplant: review of the recent data and current practices in Canada","volume":"31","author":"Ratiu","year":"2024","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.052_bib0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hon.2841","article-title":"Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia","volume":"39","author":"Meng","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.052_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.052_bib0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.052_bib0018","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.04.052_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620891","article-title":"Co-reactivation of cytomegalovirus and epstein-barr virus was associated with poor prognosis after allogeneic stem cell transplantation","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.052_bib0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.23452","article-title":"Molecular monitoring and stepwise preemptive therapy for epstein\u2013barr virus viremia after allogeneic stem cell transplantation","volume":"88","author":"Liu","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.052_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14471","article-title":"The IPTA nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: III - consensus guidelines for epstein-barr virus load and other biomarker monitoring","volume":"28","author":"Preiksaitis","year":"2024","journal-title":"Pediatr Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.052_bib0022","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2141.2011.08855.x","article-title":"Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of epstein\u2013barr virus-associated lymphoproliferative disease following stem cell transplantation","volume":"155","author":"Worth","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.052_bib0023","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/bmt.2014.298","article-title":"Impact of epstein barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab","volume":"50","author":"Garc\u00eda-Cadenas","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.052_bib0024","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/tid.12061","article-title":"Prognostic factors and outcome of E pstein\u2013 B arr virus DNA emia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab","volume":"15","author":"Patriarca","year":"2013","journal-title":"Transpl Infect Dis"},{"issue":"17","key":"10.1016\/j.jtct.2026.04.052_bib0025","first-page":"2062","article-title":"How I prevent viral reactivation in high-risk patients","volume":"141","author":"Dadwal","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.052_bib0026","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41409-023-02129-7","article-title":"Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of infectious diseases working party EBMT","volume":"59","author":"Styczynski","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.052_bib0027","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of epstein-barr virus\u2013lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation","volume":"99","author":"Van Esser","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.052_bib0028","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-019-0699-6","article-title":"Pre-emptive rituximab treatment for epstein\u2013barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes","volume":"55","author":"Stocker","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.052_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.052_bib0030","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1139274","article-title":"Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.052_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2026.04.052_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.865170","article-title":"Features of epstein\u2013barr virus and cytomegalovirus reactivation in acute leukemia patients after haplo-HCT with myeloablative ATG-containing conditioning regimen","volume":"12","author":"Ru","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.052_bib0033","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:52:06Z","timestamp":1788987126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003386"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.052","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Low-Dose Rituximab as Preemptive Treatment of EBV DNA-emia After Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}